Imatinib in Dermatofibrosarcoma: Targeted Therapy or Immunotherapy?

There is increasing evidence that certain kinase inhibitors are able to foster two strategies, i.e. inhibition of oncogenic activated molecular pathways and modulation of immunological processes. In this respect, the study of Tazzari et al. is of great interest because it shows both effects for the kinase inhibitor imatinib in dermatofibrosarcoma protuberans.